Combination therapy with anti‐CTLA4 and ES‐072 significantly increased the total and activated level of CD8+ cytotoxic T cells in the tumor compared with monotherapy, displaying a greater synergistic effect.[416] However, in clinical trials, the combination of anti‐CTLA4 antibodies and EGFR‐TKIs has not demonstrated satisfactory therapeutic effects. This evidence concerns the gene CD8A and neoplasm.